| Outcome Measures: |
Primary: HbA1c change from baseline at week 28, Baseline, 28 weeks | Secondary: percent change from baseline in body weigh, Baseline, 28 weeks|Proportion of subjects with HbA1c <7.0% and weight loss ≥5% from baseline, Baseline, 28 weeks|Change from baseline in HbA1c (superiority), Baseline, 28 weeks|Proportion of subjects with HbA1c <7.0%, Baseline, 28 weeks|Safety,Incidence and severity of adverse events and correlation with study drug;, Baseline to 32weeks|Time to peak plasma concentration (Tmax), Baseline to 28weeks|Time to peak plasma concentration (Cmax), Baseline to 28weeks|area under curve (AUC), Baseline to 28weeks|volume distribution (V), Baseline to 28weeks|half-life (half-life, T1/2, Baseline to 28weeks|clearance rate (clearance, CL), Baseline to 28weeks|To assess changes in PD parameters fasting insulin at different time points before and after administration., Baseline to 28weeks|To assess changes in PD parameters fasting C-peptide at different time points before and after administration., Baseline to 28weeks
|
